The world leader in Vitamin K2 as MK-7 expands its product portfolio, developing a new
ingredient with a technologically advanced delivery system for fast-growing,
dynamic supplement categories

 

OSLO, NORWAY (13 FEB 2019) — NattoPharma has reached an accord with Inventia Healthcare Ltd. and Laila Nutraceuticals that provides NattoPharma with the exclusive rights in core markets to add Inventia and Laila’s proprietary ingredient, in the mood and energy segments, supported by unique composition of actives and proprietary novel technology, to its clinically validated portfolio.

Not only does the agreement bring an exciting innovation to a dynamic ingredient category, but it is also the first ingredient NattoPharma will introduce separate from the Vitamin K2 as menaquinones segment.

“NattoPharma has been incubating a number of new concepts based on our high standard of clinical  validation confirming true health benefits,” says NattoPharma CEO Kjetil Ramsøy. “Laila’s long, rich history in developing superior actives and Inventia’s entry into Nutraceuticals with its pharmaceutical background equates to tighter product specifications, stringent quality standards, and an insistence upon delivering products based on science, which is perfectly in line with NattoPharma’s principles.”

“We are delighted to partner with Inventia and NattoPharma to bring Nutraceutical Ingredients to the market that address consumer needs and are backed by robust science and quality,” says Kiran Bhupathiraju, CEO Laila Nutraceuticals.

“We are excited to sign this agreement with NattoPharma, as it combines the market reach of NattoPharma, superior active from Laila, along with the technology advantage of Inventia Healthcare to
provide customers with more benefits,” says Vishal Shah, Whole Time Director at Inventia. “Our three companies are likeminded in holding ourselves to the highest standards, ensuring the ingredients we put
in the marketplace are supported by substantial evidence confirming efficacy and safety. This partnership further validates the application of our diverse delivery platforms and its applications in the Nutritional space for the betterment of human health.”

Inventia Healthcare Ltd. is a 33-year-old innovative drug delivery company that specializes in novel, science-based, oral delivery technologies for Pharmaceutical applications. With a state-of-the-art research and development center approved by the Ministry of Science and Technology, Government of India, Inventia is well equipped to undertake formulation and development projects on Novel Drug Delivery Systems in the Nutraceuticals segment.

Laila Nutraceuticals is a world leader in developing innovative botanical ingredients that have become top sellers across various countries over the last several decades. With a rich heritage of 44 years, Laila Nutraceuticals has state of the art GLP laboratories with 150 scientists dedicated to research and innovation of botanical actives coupled with cGMP compliant, NSF GMP certified manufacturing facilities that have been approved by US FDA and other regulatory agencies.

Ramsøy adds, “Inventia’s delivery technology and Laila’s superior ingredient composition is a perfect complement to our existing ingredient family in that it has a long history of safe use, along with the requisite clinical evidence that our customers demand and expect. We continue in the substantiation process, including human clinical studies validating superior health benefits, which signify real process for our project. Given the sales cycle and timing, we would expect to begin realizing commercial sales in Q1 2020.”

XXX

About NattoPharma and MenaQ7®
NattoPharma ASA, based in Norway, is the supplement industry world leader in vitamin K2 research and development. NattoPharma is the exclusive international supplier of MenaQ7® Vitamin K2 as MK-7, the best documented, vitamin K2 as menaquinone-7 (MK-7) with guaranteed actives and stability, clinical substantiation, and international patents granted and pending; and now the new MenaQ7® Full Spectrum, which delivers menaquinones 6, 7, and 9. The company has a multi-year research and development program to substantiate and discover the health benefits of Vitamin K2 for applications in the marketplace for functional food and dietary supplements, in addition to exclusive access to the research efforts of its pharmaceutical arm, Kaydence Pharma AS (est. 2017), outside of the pharmaceutical domain. With a global presence, the company established its North American subsidiary, NattoPharma USA, Inc., in Edison, NJ, and NattoPharma R&D Ltd. in Cyprus. For more information, visit www.nattopharma.com or www.menaq7.com.

For more information, please contact:
Kate Quackenbush, NattoPharma Director of Communications
Phone: 609-643-0749 x 220; E-mail: kate.quackenbush@nattopharma.com